



FAQs on Intravesical Immunotherapy for Superficial Bladder Cancer

CME Instructions

This activity comprises four parts to be sent to you throughout the year. To earn credit, you must read and complete all four parts. To receive documentation of your participation in this four-part CME activity for a total of 1 hour of CME credit, please complete the following steps:

- 1. Read each newsletter.
2. Complete the CME posttest included in each of the four parts.
3. Mail or fax each of the completed posttests to Projects In Knowledge, One Harmon Plaza, Secaucus, NJ 07094; fax: 1-201-617-7333.*
4. After reading the final part, complete the CME evaluation survey contained therein.
5. Mail or fax your final posttest and the CME evaluation survey to Projects In Knowledge at the address and fax number above.

CME Certificate

*At the end of the series, Projects In Knowledge will mail you an acknowledgment of your participation in this activity if your combined score for all four posttests is 70% or higher. If your combined score is lower than 70%, you will be notified by mail and given an opportunity to take a single test covering information from all four issues of the newsletter.

Name _____ Degrees/Credentials _____

Mailing Address _____

City _____ State _____ ZIP _____

Phone # _____ Fax # _____

E-mail _____

Please indicate your answers below (circle one).

- 1. In general, patients who have a recurrence of nonaggressive TCC after completing induction therapy with BCG/interferon should:
a. Still proceed with the usual maintenance therapy regimen
b. Receive another course of induction therapy using the same doses (1/3-dose BCG + 50 mIU IFN)
c. Receive another course of induction therapy using lower-dose BCG and higher-dose interferon (1/10-dose BCG + 100 mIU interferon)
d. Discontinue BCG/interferon and be considered for alternative intravesical therapy or cystectomy
2. Following treatment with BCG or BCG/interferon, what is the minimum recommended time before a cystoscopy should be performed?
a. Can be performed within 24 hours
b. 10 to 14 days
c. 4-6 weeks
d. At least 3 months
3. When administering BCG/interferon combination therapy, which form of interferon should be used?
a. The powder
b. The solution
c. Either one is acceptable
4. For a patient who experiences BCG side effects, the dose should be reduced in increments of one third, with the lowest recommended dose being:
a. 1/3 c. 1/30
b. 1/10 d. 1/100